The Benefit of Hippotherapy in Stroke Patients

July 27, 2022 updated by: Helena Cassol, Centre Hospitalier Universitaire de Liege

The Benefit of Hippotherapy in the Therapeutic Management of Stroke Patients in Sequel Phase

This study aims to explore the interest of hippotherapy in the management of patients with stroke in the sequelae phase by evaluating the psychological and physical well-being. It is a controlled and randomized prospective longitudinal study.

Hippotherapy is a rehabilitation method entrusted to a paramedical or medical profession that uses the horse in its treatment program in addition to conventional medical care.

Hippotherapy has benefits at the psychomotor and motor level. The method is based on the use of the horse's characteristic movements when walking to provide sensory information and to induce motor adjustment responses mainly at the level of the pelvis and the trunk of the rider in order to work on balance, postural control, muscle tone and joint mobility of the patient sitting on his back. In particular for people with paresis or plegia sequelae, it contributes to rehabilitation programs. In addition, by inducing a helical movement of the pelvis, the horse's walk reproduces in the the disabled rider a pattern of trunk reactions very similar to that of the normal human walking pattern. This pattern can be integrated as a normal sensorimotor reaction and help the patient to improve his sitting balance and his coordination.

Hippotherapy is also interesting because getting out of the traditional rehabilitation framework and being in contact with an imposing animal has positive repercussions on the psyche and therefore on functional recovery.

All patients will undergo an assessment that will focus on their physical and psychological well-being at the beginning and end of the study as well as during a follow-up at 2 weeks, one month and 3 months.

Patients assigned to the experimental group (EG) will receive, in addition to their physical therapy, a weekly hippotherapy session of 30 minutes. The follow-up will take place during 3 months for a total of 12 sessions. The EG will also be monitored in the short term (before and after each session) for well-being and fatigue.

Quality of life will be explored using the SF-36 questionnaire and the SS-QOL scale. Self-esteem will be measured using the Rosenberg scale. Patients' physical abilities will be assessed with functional tests, standing balance measurements on a strength platform and the ABC-S self-evaluation scale.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • patients who have suffered a stroke and who are in a sequelae phase (after hospitalization or discharge from the rehabilitation center)
  • patients who have sufficient trunk balance to hold on to the horse
  • patients who have the consent of their doctor
  • patients who indicated their agreement to participate in the study by signing the consent form

Exclusion Criteria:

  • pressure sore at the seat level
  • other lesion or neurological history
  • severe cognitive deficits affecting the understanding
  • do not understand French language
  • allergy to horses
  • weigh more than 100 kg
  • acute pain syndrome
  • epilepsy
  • patient has benefited from hippotherapy sessions during the last 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Hippotherapy
The experimental group will receive 30 minutes of hippotherapy once a week for 12 weeks.
Hippotherapy is a rehabilitation method entrusted to a paramedic or medical practitioner who uses the horse in his/her program treatment, in addition to conventional medical care.
No Intervention: Control
The control group will receive its rehabilitation care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The stroke specific quality of life (SS-QOL)
Time Frame: 12 weeks

The SS-QOL, which is a disease-specific quality of life measure, consists of 49 items encompassing 12 domains, which include the social role (five questions), mobility (six questions), energy (three questions), language (five questions), self-care (five questions), mood (five questions), personality (three questions), thinking (three questions), upper extremity function (five questions), family role (three questions), vision (three questions), and work/productivity (three questions). Each item is ranked on a five-point Likert scale in which level one means completely agreed while level five means completely disagree. The summary score of this scale is an un-weighted average of the 12 domains. The total score ranges from 49 to 245, with higher scores indicating a better QOL.

Scale

12 weeks
36-Item Short Form Survey Instrument (SF-36)
Time Frame: 12 weeks
The Short Form 36 Health Survey Questionnaire (SF-36) is used to indicate the health status of particular populations, to help with service planning and to measure the impact of clinical and social interventions. It is composed of 8 domains assessing quality of life which enable to obtain two composite scores. Higher scores correspond to a higher quality of life.
12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rosenberg self-esteem scale
Time Frame: 12 weeks
A 10-item scale that measures global self-worth by measuring both positive and negative feelings about the self. The scale is believed to be uni-dimensional. All items are answered using a 4-point Likert scale format ranging from strongly agree to strongly disagree. A higher score corresponds to a higher self-esteem.
12 weeks
Timed up & go
Time Frame: 12 weeks

At the signal from the assessor ("Go ahead"), the person should stand up and walk away.

a comfortable and safe speed up to a line drawn on the floor (3 m further), turn, then come back and sit down. A first attempt should be made to familiarize the person with the test. The test therefore comprises an exercise and subsequently an "official" test. Results: the investigator starts the timing at "Go ahead" and stops it when the person has returned to a seated position.

The time of the course (in seconds) is retained as the final score. The test will be judged positive (mobility disorders, risk of falling) if the score exceeds 12 to 14 seconds.

12 weeks
The Tinetti test
Time Frame: 12 weeks
The Tinetti test was published by Mary Tinetti (Yale University) to assess the gait and balance in older adults and to assess perception of balance and stability during activities of daily living and fear of falling. It is also called Performance-Oriented Mobility Assessment (POMA). It also is a very good indicator of the fall risk of an individual. It has better test-retest, discriminative and predictive validities concerning fall risk than other tests including Timed Up and Go test (TUG), one-leg stand and functional reach test. The total score is 28. A total score below 26 indicates a problem. the lower the score, the bigger the problem. A score below 19 means that the risk of falling is multiplied by five.
12 weeks
Timed chair stand test
Time Frame: 12 weeks
The 30-second chair stand involves recording the number of stands a person can complete in 30 seconds rather then the amount of time it takes to complete a pre-determined number of repetitions.
12 weeks
Strength platform
Time Frame: 12 weeks
Strength platform/Force plates are used to measure the efforts of activities such as walking or running. They deliver precise and reliable results for gait analysis, very useful in many fields such as research, rehabilitation, occupational therapy and fitting of prostheses.
12 weeks
The Activities-Specific Balance Confidence Scale (ABC Scale)
Time Frame: 12 weeks
The ABC Scale is an 16 point self-report measure of balance confidence in performing various activities without losing balance or experiencing a sense of unsteadiness. Each item is ranked on a four-point Likert scale. A higher score corresponds to a higher level of confidence.
12 weeks
Well-being and fatigue
Time Frame: 12 weeks
Well-being and fatigue will also be assessed using numerical scales ranging from 0 to 10, before and after each hippotherapy session. Higher scores indicate a lower level of well-being and a higher level of fatigue.
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2022

Primary Completion (Anticipated)

January 1, 2023

Study Completion (Anticipated)

January 1, 2025

Study Registration Dates

First Submitted

April 6, 2022

First Submitted That Met QC Criteria

April 19, 2022

First Posted (Actual)

April 26, 2022

Study Record Updates

Last Update Posted (Actual)

July 28, 2022

Last Update Submitted That Met QC Criteria

July 27, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Hippotherapy

Subscribe